Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints
All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.
The Pharma Letter11h
Amgen and Kyowa Kirin announce rocatinlimab Phase III success
US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...
Fierce Biotech13h
Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Amgen And Kyowa Kirin Provide Top-line Results From Rocatinlimab Phase 3 Ignite Study In Adults With Moderate To Severe Atopic Dermatitis
Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...